Hamjane Nadia, Mechita Mohcine Bennani, Nourouti Naima Ghailani, Barakat Amina
Research Team in Biomedical Genomics and Oncogenetics, Faculty of Sciences and Technology of Tangier, Abdelmalek Essaadi University, Morocco.
Research Team in Biomedical Genomics and Oncogenetics, Faculty of Sciences and Technology of Tangier, Abdelmalek Essaadi University, Morocco.
Microvasc Res. 2024 Jan;151:104601. doi: 10.1016/j.mvr.2023.104601. Epub 2023 Sep 9.
Obesity is a complex, multifactorial disease caused by various factors. Recently, the role of the gut microbiota in the development of obesity and its complications has attracted increasing interest.
This article focuses on the mechanisms by which gut microbiota dysbiosis induces insulin resistance, type 2 diabetes, and cardiovascular diseases linked to obesity, highlighting the mechanisms explaining the role of gut microbiota dysbiosis-associated inflammation in the onset of these pathologies.
A systematic study was carried out to understand and summarize the published results on this topic. More than 150 articles were included in this search, including different types of studies, consulted by an online search in English using various electronic search databases and predefined keywords related to the objectives of our study.
We have summarized the data from the articles consulted in this search, and we have found a major gut microbiota alteration in obesity, characterized by a specific decrease in butyrate-producing bacteria and the production of metabolites and components that lead to metabolic impairments and affect the progression of various diseases associated with obesity through distinct signaling pathways, including insulin resistance, type 2 diabetes, and cardiovascular diseases (CVD). We have also focused on the major role of inflammation as a link between gut microbiota dysbiosis and obesity-associated metabolic complications by explaining the mechanisms involved.
Gut microbiota dysbiosis plays a crucial role in the development of various obesity-related metabolic abnormalities, among them type 2 diabetes and CVD, and represents a major challenge for chronic disease prevention and health. Indeed, the intestinal microbiota appears to be a promising target for the nutritional or therapeutic management of these diseases.
肥胖是一种由多种因素引起的复杂的多因素疾病。最近，肠道微生物群在肥胖及其并发症发生发展中的作用引起了越来越多的关注。
本文重点关注肠道微生物群失调诱导胰岛素抵抗、2型糖尿病以及与肥胖相关的心血管疾病的机制，突出解释肠道微生物群失调相关炎症在这些疾病发病中作用的机制。
开展了一项系统性研究，以理解和总结关于该主题已发表的研究结果。本次检索纳入了150多篇文章，包括不同类型的研究，通过使用各种电子搜索数据库以及与我们研究目标相关的预定义关键词，以英文进行在线搜索获取。
我们总结了本次检索中查阅文章的数据，发现肥胖患者存在主要的肠道微生物群改变，其特征是产丁酸菌特异性减少，以及产生导致代谢受损并通过不同信号通路影响与肥胖相关的各种疾病进展的代谢产物和成分，这些疾病包括胰岛素抵抗、2型糖尿病和心血管疾病（CVD）。我们还通过解释其中涉及的机制，重点关注了炎症作为肠道微生物群失调与肥胖相关代谢并发症之间联系的主要作用。
肠道微生物群失调在各种与肥胖相关的代谢异常（包括2型糖尿病和CVD）的发生发展中起关键作用，是慢性病预防和健康面临的重大挑战。事实上，肠道微生物群似乎是这些疾病营养或治疗管理的一个有前景的靶点。
